Spatially Resolved Heterogeneity of Triple Negative Breast Cancer

In cases of triple negative breast cancer, where hormone therapies and targeted anti-HER2 treatment are ineffective, surgical resection of cancerous tissue often becomes the first line of defense. Triple negative breast cancer (TNBC) is unresponsive to traditional hormone or targeted therapies and highly heterogeneous. Download this application note and learn about spatially resolved heterogeneity of triple negative breast cancer.

Oops! It looks like there were some errors.

Please check the highlighted fields and try again.

Download Now

login

Name*
Company/Institution *
Institution Type *
Address*
Email Address *
Area of Research *
I agree to receive e-mails from 10x Genomics, Inc. and its subsidiaries regarding its products, user events, and other communications *
Yes
No
Email & Subscription Preferences
Topic - Specific eNewslettersNew Product Announcements and Special Offers from our trusted life science partners
Future Lab Topics
Trends in Live Cell ImagingTrends in Protein ProductionTrends in ImmunodetectionEstablishing and Maintaining a Cell Culture FacilityTrends in Flow CytometryAutomation in Drug DiscoveryTrends in Next Gen SequencingTrends in COVID-19 R&DTrends in Genomic ScreeningTrends in GenomicsAntibody-Based TherapeuticsOptimizing workflows

By submitting this form, you consent to Biocompare storing your email address and contact information and transmitting your contact information to the Future Lab sponsor. You also agree to receive email from Biocompare and the sponsor. You may request to be removed at any time.

Facebook

Email